Logo

Activx Partners with Gilead Sciences

Apr 09, 2004

NEW YORK, April 9 (GenomeWeb News) - Activx Biosciences announced this week that it will apply its activity proteomics technology to characterize the activities of compounds for Foster City, Calif.-based Gilead Sciences.

Activx has similar deals already with Pfizer and Kyorin Pharmaceuticals.

Financial terms of the deal were not disclosed.

 

Breaking News
The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.